AML patients with IDH1/2 mutations have poor prognosis, generally with low white blood cell counts and high platelet counts, especially when accompanied by other mutations, such as NMP1 and FLT3-ITD. The gene discussed is IDH1; the disease is acute myeloid leukemia.